Related Experiment Videos
Ifosfamide in non-small cell lung cancer
1Department of Medicine, Division of Medical Oncology, The Vanderbilt Clinic, Nashville, TN 37232-5536, USA.
Seminars in Oncology
|June 1, 1996
Summary
Ifosfamide shows promise against solid tumors like non-small cell lung cancer, with manageable toxicity when combined with mesna. While it improves response rates in combination therapies, survival benefits require further investigation.
Area of Science:
- Oncology
- Pharmacology
Background:
- Ifosfamide, a cyclophosphamide analogue, demonstrates activity against various solid tumors.
- Preclinical data suggest response rates of 20-25% and median survival of 4-5 months.
Purpose of the Study:
- To review the efficacy and toxicity of ifosfamide in cancer treatment.
- To explore the impact of administration schedules and combinations on ifosfamide's effectiveness.
Main Methods:
- Review of preclinical and clinical studies on ifosfamide.
- Analysis of combination therapy outcomes and toxicity profiles.
Main Results:
- Hematologic toxicity is a primary concern, mitigated by mesna.
- Oral ifosfamide administration increases neurotoxicity but does not affect response rates.
- Combination therapies, including with cisplatin, etoposide, vinorelbine, and paclitaxel, show improved response rates.
- Randomized phase II trials indicate no significant survival benefit with ifosfamide addition to established regimens.
Conclusions:
- Ifosfamide is a viable option for solid tumors, with toxicity manageable by mesna.
- Further research into ifosfamide combinations with novel agents is warranted to explore potential survival advantages.